AZ claims full control of Caelum’s AL amyloidosis drug in $500m dealAstraZeneca’s newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal Share XAZ claims full control of Caelum’s AL amyloidosis drug in $500m dealhttps://pharmaphorum.com/news/az-claims-full-control-of-caelums-al-amyloidosis-drug-in-500m-deal/
After Ultomiris stumble, Alexion delivers a rare disease win for AZA drug for Wilson disease developed by AstraZeneca’s Alexion rare disease unit has cleared a phase 3 trial, Share XAfter Ultomiris stumble, Alexion delivers a rare disease win for AZhttps://pharmaphorum.com/news/after-ultomiris-stumble-alexion-delivers-a-rare-disease-win-for-az/
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialIt has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new Share XAZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialhttps://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Another hurdle down as EU clears AstraZeneca’s Alexion takeoverThe European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the Share XAnother hurdle down as EU clears AstraZeneca’s Alexion takeoverhttps://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
UK competition watchdog probes AstraZeneca, Alexion mergerThe antitrust authority in the UK has launched an investigation into the proposed $39 billion takeover of US Share XUK competition watchdog probes AstraZeneca, Alexion mergerhttps://pharmaphorum.com/news/uk-competition-watchdog-probes-astrazeneca-alexion-merger/
Apellis set to take on Alexion as FDA clears PNH drug EmpaveliApellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal Share XApellis set to take on Alexion as FDA clears PNH drug Empavelihttps://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/
